The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to Growth Hormone (GH)
Authors' conclusion
While this miRNA panel identified treatment-responsive miRNAs, it did not correlate with growth outcomes. Increasing the sample size and incorporating additional miRNAs could enhance its clinical utility for predicting GH treatment sensitivity in GHD patients.
Study context
- Population
- Prepubertal children with growth hormone deficiency (GHD) treated with daily rhGH (0.033 mg/kg) for 6 months3 excluded or withdrew
- Participants
- 16 children
- Exposure
- Circulating miRNA levels during rhGH therapy; treatment-naïve vs prior GH therapy
- Outcome
- Circulating levels of six miRNAs (miR-22-3p, miR-30c-5p, miR-140-5p, miR-340-5p, miR-494-3p, miR-16-5p) by digital PCR
- Follow-up
- Baseline, 1, 3 and 6 months
Main finding
As reported in the abstract
- All microRNAs (miRNAs): significant increases at 1 and 6 months, with a transient decline at 3 months
- No significant correlations between miRNA levels and growth velocity, height SDS or IGF-1 levels
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Height-SDS gains, treatment-naïve vs prior GH therapyGreater height-SDS gains with treatment-naïve | P = 0.008 |
miRNA expression, treatment-naïve vs prior GH therapy
- No differences in miRNA expression between groups; no correlation between miRNA levels and height-SDS increments
Original publication
The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH. Clin Endocrinol (Oxf). Published 20 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →